Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS
J Clin Oncol. 2014 32 (10): 1020-30

PMID: 24590637 · PMCID: PMC4811023 · DOI:10.1200/JCO.2013.53.0105

MeSH Terms (13)

Adult Antibodies, Monoclonal Antineoplastic Agents Disease-Free Survival Female Humans Kaplan-Meier Estimate Male Melanoma Middle Aged Nivolumab Skin Neoplasms Survival Rate

Connections (1)

This publication is referenced by other Labnodes entities: